Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$13.95 +5.3%	$13.84	$10.57 ▼ $33.33	$2.03B	1.49	1.12 million shs	2.15 million shs
HRMY Harmony Biosciences	$35.55 +3.0%	$31.54	$26.47 ▼ $41.61	$2.04B	0.82	608,978 shs	421,106 shs
KNSA Kiniksa Pharmaceuticals	$27.89 +2.0%	$23.62	$17.38 ▼ $28.56	$2.04B	0.07	492,712 shs	531,127 shs
RLAY Relay Therapeutics	$3.16 +5.2%	$2.79	$1.78 ▼ $10.72	$540.91M	1.65	2.08 million shs	1.40 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	0.00%	-1.79%	-19.83%	-13.29%	-28.99%
HRMY Harmony Biosciences	0.00%	+0.61%	+13.39%	+6.84%	+16.94%
KNSA Kiniksa Pharmaceuticals	0.00%	+2.01%	-0.80%	+27.82%	+44.29%
RLAY Relay Therapeutics	0.00%	+3.44%	-7.38%	-5.94%	-53.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.3415 of 5 stars	4.5	1.0	4.7	3.0	2.5	0.0
HRMY Harmony Biosciences	4.9402 of 5 stars	4.6	4.0	0.0	3.6	3.3	4.4
KNSA Kiniksa Pharmaceuticals	2.7884 of 5 stars	3.5	2.0	0.0	2.7	3.3	0.6
RLAY Relay Therapeutics	2.2189 of 5 stars	3.4	1.0	0.0	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	141.77% Upside
HRMY Harmony Biosciences	3.11	Buy	$53.00	49.08% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	39.10% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	459.96% Upside

Current Analyst Ratings Breakdown

Latest RLAY, KNSA, HRMY, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	6.13	N/A	N/A	$7.42 per share	1.88
HRMY Harmony Biosciences	$744.85M	2.74	$2.66 per share	13.38	$7.97 per share	4.46
KNSA Kiniksa Pharmaceuticals	$481.17M	4.23	N/A	N/A	$6.23 per share	4.48
RLAY Relay Therapeutics	$7.68M	70.44	N/A	N/A	$5.90 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/30/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.85	11.43	0.47	17.98%	23.16%	14.24%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	111.58	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
RLAY Relay Therapeutics	-$341.97M	-$2.23	N/A	N/A	N/A	N/A	-45.75%	-40.75%	8/5/2025 (Estimated)

Latest RLAY, KNSA, HRMY, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.98	9.98
HRMY Harmony Biosciences	0.28	3.24	3.20
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
RLAY Relay Therapeutics	N/A	18.42	18.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
HRMY Harmony Biosciences	86.23%
KNSA Kiniksa Pharmaceuticals	53.95%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
HRMY Harmony Biosciences	23.60%
KNSA Kiniksa Pharmaceuticals	54.57%
RLAY Relay Therapeutics	4.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
RLAY Relay Therapeutics	330	171.45 million	160.15 million	Optionable

RLAY, KNSA, HRMY, and DNLI Headlines

Recent News About These Companies

Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025

June 2 at 7:00 AM | globenewswire.com

Two Sigma Investments LP Sells 199,482 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 31 at 3:47 AM | marketbeat.com

Relay Therapeutics (NASDAQ:RLAY) Shares Up 5.1% - Here's What Happened

May 30 at 3:16 PM | marketbeat.com

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

May 29, 2025 | globenewswire.com

Relay Therapeutics’ SWOT analysis: ai-driven biotech stock faces pivotal year

May 29, 2025 | investing.com

Voloridge Investment Management LLC Cuts Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 29, 2025 | marketbeat.com

Man Group plc Buys Shares of 173,605 Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 27, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares Purchased by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Buys 231,713 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 24, 2025 | marketbeat.com

What Makes Relay Therapeutics (RLAY) a New Buy Stock

May 23, 2025 | zacks.com

BNP Paribas Financial Markets Invests $987,000 in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 23, 2025 | marketbeat.com

Point72 Asset Management L.P. Raises Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 22, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) is Tang Capital Management LLC's 9th Largest Position

May 20, 2025 | marketbeat.com

180,000 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Acquired by Raiffeisen Bank International AG

May 19, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Consensus Recommendation of "Moderate Buy" by Analysts

May 18, 2025 | marketbeat.com

MPM Bioimpact LLC Has $9.35 Million Stock Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 16, 2025 | marketbeat.com

Parkman Healthcare Partners LLC Takes $2.06 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 16, 2025 | marketbeat.com

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)

May 16, 2025 | marketbeat.com

Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Zura Bio (ZURA)

May 15, 2025 | theglobeandmail.com

692,279 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Bought by Balyasny Asset Management L.P.

May 14, 2025 | marketbeat.com

Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now

May 13, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, KNSA, HRMY, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$13.94 +0.71 (+5.32%)

Closing price 03:59 PM Eastern

Extended Trading

$13.71 -0.23 (-1.68%)

As of 04:09 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$35.55 +1.05 (+3.05%)

Closing price 03:59 PM Eastern

Extended Trading

$35.56 +0.01 (+0.02%)

As of 04:04 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$27.89 +0.53 (+1.95%)

Closing price 03:59 PM Eastern

Extended Trading

$27.92 +0.03 (+0.09%)

As of 04:01 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Relay Therapeutics NASDAQ:RLAY

$3.16 +0.16 (+5.17%)

Closing price 03:59 PM Eastern

Extended Trading

$3.17 +0.02 (+0.48%)

As of 04:12 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time